Advertisement

Measurements of Antihypertensive Medications in Blood and Urine

  • Pankaj Gupta
  • Prashanth Patel
  • Maciej Tomaszewski
Chapter
Part of the Updates in Hypertension and Cardiovascular Protection book series (UHCP)

Abstract

Biochemical detection of antihypertensive medications in blood and urine is a recent addition to the diagnosis of therapeutic non-adherence. The biochemical analysis by high performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) provides a direct, objective and robust confirmation of the presence or absence of prescribed antihypertensive medications in bodily fluids. This chapter covers the laboratory principles and the clinical aspects of the biochemical screening for therapeutic non-adherence in management of hypertension.

Keywords

Biochemical screening Adherence Non-adherence Liquid chromatography mass spectrometry Hypertension Cardiovascular disease Blood pressure 

Notes

Acknowledgment

The authors are grateful to Dan Lane in the Department of Chemical Pathology and Metabolic Disease, Leicester Royal Infirmary who prepared the illustrations used in this chapter. Our work on adherence is supported by British Heart Foundation Clinical Study (CS/17/3/32799).

References

  1. 1.
    Hesse G, Weil H. Michael Tswett’s first paper on chromatography. Eschwege: M. Woelm; 1954.Google Scholar
  2. 2.
    IUPAC. Compendium of chemical terminology, 2nd ed. (the “Gold Book”). Compiled by McNaught AD, Wilkinson A. Oxford: Blackwell Scientific Publications; 1997. XML on-line corrected version: http://goldbook.iupac.org (2006-) created by M. Nic, J. Jirat, B. Kosata; updates compiled by A. Jenkins. ISBN 0–9678550–9-8. 2014;  https://doi.org/10.1351/goldbook. Accessed 4 Sept 2017.
  3. 3.
    Thomson J. On the cathode rays. Proc Camb Philos Soc. 1897;9:243–4.Google Scholar
  4. 4.
    Fenn JB, Mann M, Meng CK, Wong SF, Whitehouse CM. Electrospray ionization for mass spectrometry of large biomolecules. Science. 1989;246:64–71.CrossRefPubMedGoogle Scholar
  5. 5.
    Grebe SK, Singh RJ. LC-MS/MS in the clinical laboratory—where to from here? Clin Biochem Rev. 2011;32:5–31.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Mbughuni MM, Jannetto PJ, Langman LJ. Mass spectrometry applications for toxicology. EJIFCC. 2016;27:272–87.PubMedPubMedCentralGoogle Scholar
  7. 7.
    WADA. Minimum criteria for chromatographic mass spectrometric confirmation of the identity of analytes for doping control purpose (TD2015IDCR). 2015. www.wada-ama.org/sites. Accessed 4 Aug 2017.
  8. 8.
    Pitt JJ. Principles and applications of liquid chromatography-mass spectrometry in clinical biochemistry. Clin Biochem Rev. 2009;30:19–34.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Tomaszewski M, White C, Patel P, Masca N, Damani R, Hepworth J, et al. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart. 2014;100:855–61.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;12:766–74.CrossRefGoogle Scholar
  11. 11.
    Strauch B, Petrak O, Zelinka T, Rosa J, Somloova Z, Indra T, et al. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. J Hypertens. 2013;31:2455–61.CrossRefPubMedGoogle Scholar
  12. 12.
    Ceral J, Habrdova V, Vorisek V, Bima M, Pelouch R, Solar M. Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy. Hypertens Res. 2011;34:87–90.CrossRefPubMedGoogle Scholar
  13. 13.
    Brinker S, Pandey A, Ayers C, Price A, Raheja P, Arbique D, et al. Therapeutic drug monitoring facilitates blood pressure control in resistant hypertension. J Am Coll Cardiol. 2014;63:834–5.CrossRefPubMedGoogle Scholar
  14. 14.
    Ewen S, Meyer MR, Cremers B, Laufs U, Helfer AG, Linz D, et al. Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysis. Clin Res Cardiol. 2015;104:1097–105.CrossRefPubMedGoogle Scholar
  15. 15.
    Lawson AJ, Shipman KE, George S, Dasgupta I. A novel ‘dilute-and-shoot’ liquid chromatography-tandem mass spectrometry method for the screening of antihypertensive drugs in urine. J Anal Toxicol. 2016;40:17–27.PubMedGoogle Scholar
  16. 16.
    Schmieder RE, Ott C, Schmid A, Friedrich S, Kistner I, Ditting T, et al. Adherence to antihypertensive medication in treatment-resistant hypertension undergoing renal denervation. J Am Heart Assoc. 2016;12:5.  https://doi.org/10.1161/JAHA.115.002343.CrossRefGoogle Scholar
  17. 17.
    Moffat A, Osselton D, Widdop B, Watts J. Clarke’s analysis of drugs and poisons. 4th ed. London: Pharmaceutical Press; 2011.Google Scholar
  18. 18.
    Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73:691–705.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Chatterjee JS. From compliance to concordance in diabetes. J Med Ethics. 2006;32:507–10.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Olsen MH, Angell SY, Asma S, Boutouyrie P, Burger D, Chirinos JA, et al. A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. Lancet. 2016;388:2665–712.CrossRefPubMedGoogle Scholar
  21. 21.
  22. 22.
    Meddings J, Kerr EA, Heisler M, Hofer TP. Physician assessments of medication adherence and decisions to intensify medications for patients with uncontrolled blood pressure: still no better than a coin toss. BMC Health Serv Res. 2012;12:270–6963.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    El Alili M, Vrijens B, Demonceau J, Evers SM, Hiligsmann M. A scoping review of studies comparing the medication event monitoring system (MEMS) with alternative methods for measuring medication adherence. Br J Clin Pharmacol. 2016;82:268–79.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Krousel-Wood M, Holt E, Joyce C, Ruiz R, Dornelles A, Webber LS, et al. Differences in cardiovascular disease risk when antihypertensive medication adherence is assessed by pharmacy fill versus self-report: the Cohort Study of Medication Adherence among Older Adults (CoSMO). J Hypertens. 2015;33:412–20.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Chan KS, Fowles JB, Weiner JP. Review: electronic health records and the reliability and validity of quality measures: a review of the literature. Med Care Res Rev. 2010;67:503–27.CrossRefPubMedGoogle Scholar
  26. 26.
    Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336:1114–7.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Hameed MA, Tebbit L, Jacques N, Thomas M, Dasgupta I. Non-adherence to antihypertensive medication is very common among resistant hypertensives: results of a directly observed therapy clinic. J Hum Hypertens. 2016;30:83–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Chowdhury R, Khan H, Heydon E, Shroufi A, Fahimi S, Moore C, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34:2940–8.CrossRefPubMedGoogle Scholar
  29. 29.
    de Jager RL, de Beus E, Beeftink MM, Sanders MF, Vonken EJ, Voskuil M, et al. Impact of medication adherence on the effect of renal denervation: the SYMPATHY trial. Hypertension. 2017;69:678–84.CrossRefPubMedGoogle Scholar
  30. 30.
    Gupta P, Patel P, Štrauch B, Lai FY, Akbarov A, Maresova V, et al. Risk factors for non-adherence to antihypertensive treatment. Hypertension. 2017;69:1113–20.CrossRefPubMedGoogle Scholar
  31. 31.
    Zolnierek KB, Dimatteo MR. Physician communication and patient adherence to treatment: a meta-analysis. Med Care. 2009;47:826–34.CrossRefPubMedGoogle Scholar
  32. 32.
    Horne R, Chapman SC, Parham R, Freemantle N, Forbes A, Cooper V. Understanding patients’ adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the Necessity-Concerns Framework. PLoS One. 2013;8:e80633.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keepanasseril A, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2014;11:CD000011.Google Scholar
  34. 34.
    World Health Organisation. Adherence to long-term therapies: evidence for action. 2003. www.who.int/chp/knowledge/publications/adherence_full_report.pdf. Accessed 12 Dec 2016.
  35. 35.
    Schroeder K, Fahey T, Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database Syst Rev. 2004;2:CD004804.Google Scholar
  36. 36.
    Patel P, Gupta PK, White CM, Stanley AG, Williams B, Tomaszewski M. Screening for non-adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation. J Hum Hypertens. 2016;30:368–73.CrossRefPubMedGoogle Scholar
  37. 37.
    Gupta P, Patel P, Štrauch B, Lai FY, Akbarov A, Gulsin GS, Beech A, Marešová V, Topham PS, Stanley A, Thurston H, Smith PR, Horne R, Widimský J, Keavney B, Heagerty A, Samani NJ, Williams B, Tomaszewski M. Biochemical screening for nonadherence is associated with blood pressure reduction and improvement in adherence. Hypertension. 2017;70:1042–8.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Chung O, Vongpatanasin W, Bonaventura K, Lotan Y, Sohns C, Haverkamp W, et al. Potential cost-effectiveness of therapeutic drug monitoring in patients with resistant hypertension. J Hypertens. 2014;32(12):2411–21.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Pankaj Gupta
    • 1
    • 2
    • 3
  • Prashanth Patel
    • 1
    • 2
  • Maciej Tomaszewski
    • 3
    • 4
  1. 1.Department of Chemical Pathology and Metabolic DiseaseUniversity Hospitals of Leicester NHS TrustLeicesterUK
  2. 2.Department of Cardiovascular SciencesUniversity of LeicesterLeicesterUK
  3. 3.Division of Cardiovascular Sciences, Faculty of Biology, Medicine and HealthUniversity of ManchesterManchesterUK
  4. 4.Division of Medicine and Manchester Heart CentreManchester University NHS Foundation Trust, Manchester Academic Health Science CentreManchesterUK

Personalised recommendations